VYGR Stock Chart & Stats
$55.00
$0.00(0.00%)
At close: 4:00 PM EDT
$55.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$46.00 - $94.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$3.02B
Enterprise Value$128.15
Total Cash (Recent Filing)$116.34M
Total Debt (Recent Filing)$32.57M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Nov 10, 2026EPS Estimate
-7.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding61,617,947
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.18
Price to Sales (P/S)5.71
P/FCF Ratio-1.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$271.20Price Target Upside393.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-28.66
Revenue Forecast (FY)$710.70M
Bulls Say, Bears Say
Bulls Say
VY1706 Safety And Efficacy EvidenceThe VY1706 data provide meaningful support for Voyager’s neurological gene-therapy platform, combining favorable non-human-primate tolerability with durable, dose-dependent tau suppression. If confirmed clinically, this profile could improve development prospects and strengthen the company’s competitive position.
Regulatory And Clinical ProgressionFDA IND clearance moves VY1706 from preclinical work into human testing, creating a structural development milestone rather than a temporary announcement. Clinical execution can generate important validation, expand partnership potential, and clarify the program’s path toward a commercial therapy.
Manageable LeverageVoyager’s relatively low debt burden provides more financial flexibility than a highly leveraged biotech would have while programs advance through clinical development. Manageable leverage may reduce near-term solvency pressure, although it does not eliminate the need to address ongoing operating losses.
Bears Say
Sharp And Sustained Revenue DeclineThe steep revenue reduction indicates that Voyager’s recent operating scale has weakened materially after the strong 2023 result. Lower collaboration or licensing-related revenue can constrain internal funding, increase dependence on new deals or financing, and make future results more volatile.
Severe Operating Cash BurnThe transition to substantial operating and free-cash-flow deficits shows that current activities consume significant cash rather than funding themselves. Persistent burn reduces strategic flexibility and raises the likelihood that Voyager will need additional financing or partnerships to sustain development.
Shrinking Equity And Persistent LossesRepeated losses are eroding Voyager’s capital base, with equity nearly halving from 2024 to the TTM period. Continued deterioration could weaken resilience, limit the company’s ability to absorb clinical setbacks, and increase pressure to secure capital on potentially unfavorable terms.
Voyager Therapeutics News
VYGR FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was $46.00 and its highest was $94.00 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Voyager Therapeutics’s market cap is $3.02B.
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 39 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on Aug 06, 2026. The company reported -$7.318 earnings per share for the quarter, beating the consensus estimate of -$8.855 by $1.537.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -7.67.
How many shares outstanding does Voyager Therapeutics have?
Voyager Therapeutics has 61,617,947 shares outstanding.
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -$7.318 in its last earnings report, beating expectations of -$8.855. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Currently, no hedge funds are holding shares in MX:VYGR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$271.20 (393.09% Upside)
$271.20 (393.09% Upside)
Blogger Sentiment
Bullish
MX:VYGR Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-42.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
VYGR Stock 12 Month Forecast
Average Price Target
$271.20
▲(393.09% Upside)